本帖最后由 老马 于 2013-3-13 13:43 编辑
$ A) x1 K3 R$ b+ ?8 q# n& ~( q0 V! Y7 V O8 D
健择（吉西他滨）+顺铂+阿瓦斯汀& _" d) ~$ D3 D' h- V& P: B. Q
Gemzar +Cisplatin + Avastin
- F* W3 b8 e4 r% chttp://annonc.oxfordjournals.org/content/21/9/1804.full/ L4 q/ g3 o. Z% {6 w' r. s
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
5 P5 ]7 c1 z, F! s% q: \Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 5 o, ]2 g% P3 A) e" P
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. + t) U7 X4 b2 q/ E2 f
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 284)
, H! @0 {$ W7 w J, O$ y
华为网盘附件：
* {; L0 A# v# v0 _, V【华为网盘】ava.JPG
9 k# w, c7 e% w |
显身卡
